Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
Clinical trial NCT03930615 · COMPLETED
Trial details
- NCT number
- NCT03930615
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-21
- Primary completion
- 2021-10-27
- Enrollment
- 220
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.